ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announces board changes with the resignation of Mr. Yu Xiaoyong as a non-executive Director, effective September 30, 2024, and the nomination of Ms. Fu Dawei for the same role, pending shareholder approval at an upcoming EGM. Ms. Fu brings over 20 years of experience in investment and technology enterprise management to ImmuneOnco’s board.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.